Les hypo-lipidémiants : Des propriétés nouvelles au fil des années, les statines et les fibrates révèlent de nouvelles propriétés. Dans le domaine de l'hta, de nouvelles études s'attachent plus précisément à en cerner les conséquences = Antilipemic agentHAÏAT, Robert.Concours médical (Paris). 2001, Vol 123, Num 10, pp 24-26, issn 0010-5309, SUPConference Paper

Elevation of CKP induced by ezetimibe in monotherapy : Report on two casesMEAS, T; CIMADEVILLA, C; TIMSIT, J et al.Diabetes & metabolism. 2006, Vol 32, Num 4, pp 364-366, issn 1262-3636, 3 p.Article

Insuffisance de la prise en charge des patients dyslipidémiques en France: Résultats de l'étude odyssées = Inadeauate management of dvslipidaemic patients in FranceFERRIERES, J; ELBAZ, M; MAUPAS, E et al.Archives des maladies du coeur et des vaisseaux. 2004, Vol 97, Num 3, pp 187-193, issn 0003-9683, 7 p.Article

Les statines en prévention primaire = Lipid-lowering therapy with statins in primary preventionPHILIPPE, Francois.STV. Sang thrombose vaisseaux. 2004, Vol 16, Num 1, pp 24-35, issn 0999-7385, 12 p.Article

Pharmacometabolomics of Statin ResponseKRAUSS, R. M; ZHU, H; KADDURAH-DAOUK, R et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 5, pp 562-565, issn 0009-9236, 4 p.Article

Études d'intervention sur les anomalies lipidiques du diabète de type 2 = Intervention studies in diabetic dyslipidaemiaVERGES, Bruno.STV. Sang thrombose vaisseaux. 2004, Vol 16, Num 6, pp 282-288, issn 0999-7385, 7 p.Article

Statins and Downstream Inhibitors of the Isoprenylation Pathway Increase Type 2 lodothyronine Deiodinase ActivityMILLER, B. T; UETA, C. B; LAU, V et al.Endocrinology (Philadelphia). 2012, Vol 153, Num 8, pp 4039-4048, issn 0013-7227, 10 p.Article

Efficacité et efficience des hypolipémiants Une analyse centrée sur les statinesAngéiologie (Paris). 2010, Vol 62, Num 4, pp 24-31, issn 0003-3049, 8 p.Article

A Current Approach to Statin IntoleranceTOMPKINS, R; SCHWARTZBARD, A; GIANOS, E et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 74-80, issn 0009-9236, 7 p.Article

Statins as Potential Antimalarial Drugs : Low Relative Potency and Lack of Synergy with Conventional Antimalarial DrugsWONG, Rina P. M; DAVIS, Timothy M. E.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 5, pp 2212-2214, issn 0066-4804, 3 p.Article

Suboptimal choices and dosing of statins at start of therapyMANTEL-TEEUWISSE, Aukje K; KLUNGEL, Olaf H; SCHALEKAMP, Tom et al.British journal of clinical pharmacology. 2005, Vol 60, Num 1, pp 83-89, issn 0306-5251, 7 p.Article

Level of awareness of on-treatment patients about prescribed statinsYILMAZ, Mehmet Birhan; BIYIKOGLU, Senay Funda; GURAY, Yesim et al.Cardiovascular drugs and therapy. 2004, Vol 18, Num 5, pp 399-404, issn 0920-3206, 6 p.Article

Effets indésirables musculaires des statines et des fibratesHILLAIRE-BVYS, Dominique.Concours médical (Paris). 2005, Vol 127, Num 34, pp 1912-1915, issn 0010-5309, 4 p.Article

The pharmaco-economics of peri-operative statin therapyBICCARD, B. M; SEAR, J. W; FOËX, P et al.Anaesthesia. 2005, Vol 60, Num 11, pp 1059-1063, issn 0003-2409, 5 p.Article

The case for statins: has it really been made?THOMPSON, Andrew; TEMPLE, Norman J.Journal of the Royal Society of Medicine. 2004, Vol 97, Num 10, pp 461-464, issn 0141-0768, 4 p.Article

L'activité antifongique des statines = Antifungal activity of statinsLEFEBVRE, M; ALSHAWA, K; DUPONT, B et al.Journal de mycologie médicale. 2010, Vol 20, Num 3, pp 212-217, issn 1156-5233, 6 p.Article

Pleiotropic effects of statins on cardiovascular events in the Japanese Coronary Artery Disease studyFUJITA, Masatoshi; YAMAZAKI, Tsutomu; HAYASHI, Doubun et al.International journal of cardiology. 2008, Vol 129, Num 2, pp 294-296, issn 0167-5273, 3 p.Article

Apport des statines en prévention cardiovasculaire = Benefits of statins in cardiovascular preventionBRUCKERT, Eric; BASTARD, Jean-Philippe.STV. Sang thrombose vaisseaux. 2009, Vol 21, Num 8, pp 347-349, issn 0999-7385, 3 p.Article

In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungiNYILASI, Iidikó; KOCSUBE, Sándor; KRIZSAN, Krisztina et al.FEMS microbiology letters. 2010, Vol 307, Num 2, pp 175-184, issn 0378-1097, 10 p.Article

Les statines peuvent-elles prévenir le risque de fractures ? = Can statins reduce risk of fracture?MEIER, C. R; SCHLIENGER, R. G; KRAENZLIN, M. E et al.La Presse médicale (1983). 2000, Vol 29, Num 38, pp 2098-2099, issn 0755-4982Article

Persistence and determinants of statin therapy among middle-aged patients for primary and secondary preventionPERREAULT, S; BLAIS, L; LAMARRE, D et al.British journal of clinical pharmacology. 2005, Vol 59, Num 5, pp 564-573, issn 0306-5251, 10 p.Article

Statins as Antithrombotic DrugsVIOLI, Francesco; CALVIERI, Camilla; FERRO, Domenico et al.Circulation (New York, N.Y.). 2013, Vol 127, Num 2, pp 251-257, issn 0009-7322, 7 p.Article

Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?BALAKUMAR, Pitchai; MAHADEVAN, Nanjaian.British journal of pharmacology. 2012, Vol 165, Num 2, pp 373-379, issn 0007-1188, 7 p.Article

Les effets indésirables des statines: diagnostic différentielDARIOLI, Roger.Angéiologie (Paris). 2011, Vol 63, Num 3, pp 19-28, issn 0003-3049, 10 p.Article

Biotechnological production and applications of statinsBARRIOS-GONZALEZ, Javier; MIRANDA, Roxana U.Applied microbiology and biotechnology. 2010, Vol 85, Num 4, pp 869-883, issn 0175-7598, 15 p.Article